Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Dumois

Gastroenterology Orlando, FL Medical Doctor

NPI 1417921115 CMS profile 63836

6735 Conroy Rd, Ste 214, Orlando, FL 32835

Open in the dashboard

General payments

$17,309

701 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Dumois of Orlando, FL is reported in the CMS Open Payments database as having received $17,309 across 701 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,097 127
2024 General $2,872 121
2023 General $2,679 98
2022 General $2,305 100
2021 General $2,342 112
2020 General $894 46
2019 General $2,119 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Dumois
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Richard Dumois were reported at $4,097. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Richard Dumois Gastroenterology median Middle half National median
2019 $2,119 $417 $126–$1,100 $163
2020 $894 $224 $74–$624 $114
2021 $2,342 $352 $106–$1,054 $132
2022 $2,305 $448 $129–$1,270 $149
2023 $2,679 $533 $150–$1,390 $160
2024 $2,872 $605 $160–$1,606 $164
2025 $4,097 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,980 164 payments
  2. Intra-Sana Laboratories $2,098 21 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $2,056 120 payments
  4. Janssen Biotech, Inc. $1,231 60 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $1,011 47 payments
  6. Pfizer Inc. $917 55 payments
  7. VIVUS, Inc. $840 41 payments
  8. Janssen Scientific Affairs, LLC $819 7 payments
  9. Nestle HealthCare Nutrition Inc. $484 18 payments
  10. Evoke Pharma, Inc. $409 11 payments
  11. Other $4,464 157 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $17,209 700 payments
  2. Education $100 1 payment
Products named General payments · program years 2019–2025
  1. RELTONE 200 MG $2,098 21 payments
  2. GLYCATE $2,098 21 payments
  3. RELTONE 400 MG $2,098 21 payments
  4. STELARA $1,610 52 payments
  5. RINVOQ $1,065 61 payments
  6. LINZESS $863 56 payments
  7. XIFAXAN $861 51 payments
  8. PANCREAZE $840 41 payments
  9. TRULANCE $829 47 payments
  10. SKYRIZI $690 34 payments
  11. Other $11,322 540 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

936

Median for Gastroenterology: 569

Drug cost

$523,580

Median for Gastroenterology: $104,976

Branded share of claims

42.1%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 54 $183,421
Sucraid Sacrosidase Brand 25 $159,782
Zenpep Lipase/Protease/Amylase Brand 22 $89,718
Linzess Linaclotide Brand 52 $52,582
Motegrity Prucalopride Succinate Brand 13 $9,869
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 51 $8,736
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 94 $5,780
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 16 $2,607
Pantoprazole Sodium Generic 240 $2,594
Sucralfate Generic 19 $2,234

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$56,671

Medicare's payments for the services billed

Medicare patients

256

Average age 72

Services billed

517

146 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Ischemic heart disease 36%
Diabetes 30%
Chronic kidney disease 22%
Cancer 18%
Heart failure 17%
Depression 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
$362 — —
SKYRIZI
$255 — —
RINVOQ
$185 — —
TREMFYA
$177 — —
PANCREAZE
$171 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

701 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record